Products Zoledronic acid is commercially available as an infusion preparation (Zometa, Aclasta, generics). It has been approved in many countries since 2000. Structure and properties Zoledronic acid (C5H10N2O7P2, Mr = 272.1 g/mol) is present in drugs as zoledronic acid monohydrate, a white crystalline powder that is sparingly soluble in water. It is an imidazole derivative … Zoledronic Acid
Products Mannitol is commercially available as a powder and as an infusion preparation. The pure substance is available in pharmacies and drugstores. Structure and properties D-mannitol (C6H14O6, Mr = 182.2 g/mol) exists as white crystals or white powder that dissolves readily in water. Mannitol is a hexavalent sugar alcohol and occurs naturally in plants, algae, … Mannitol
Products Rituximab is commercially available as a concentrate for the preparation of an infusion solution and as a solution for subcutaneous injection (MabThera, MabThera subcutaneous). It has been approved in many countries and in the United States since 1997 and in the EU since 1998. Biosimilars are available in some countries, including many (2018, Rixathon, … Rituximab
Products Mitomycin is commercially available as a powder for the preparation of a solution for injection or infusion (Mitem). Structure and properties Mitomycin (C15H18N4O5, Mr = 334.3 g/mol) exists as a blue-violet crystalline powder or as crystals and is sparingly soluble in water. It is formed by a strain of. Mitomycin was first isolated in … Mitomycin
Products Infliximab is commercially available as a powder for a concentrate for the preparation of an infusion solution (Remicade, biosimilars: Remsima, Inflectra). It has been approved in many countries since 1999. Biosimilars were released in 2015. Structure and properties Infliximab is a chimeric human murine IgG1κ monoclonal antibody with a molecular mass of 149.1 kDa … Infliximab: Drug Effects, Side Effects, Dosage and Uses
Products Infusion is the administration of a larger volume of fluid, usually intravenously into the blood, but also directly into organs or tissues. This is in contrast to injections, in which only small volumes are injected. The pharmacopoeia places special requirements on infusion preparations and the corresponding containers. Among other things, they must be germ-free, … Infusions
Products NZT is a (fictional) agent from the film (2011) based on the novel by Alan Glynn. The film was additionally followed in 2015 by a TV series with the same title, which was canceled after just one season. NZT belongs to the drug group of smart drugs. Structure and properties NZT is thallanylzirconio-methyl-tetrahydro-triazatriphenylene. The … NZT
Products Amsacrine is commercially available as an infusion preparation (Amsidyl). It has been approved in many countries since 1993. Structure and properties Amsacrine (C21H19N3O3S, Mr = 393.5 g/mol) is an aminoacridine derivative. Effects Amsacrine (ATC L01XX01) has antineoplastic properties. The effects are due to inhibition of topoisomerase II. As a result, DNA synthesis is blocked. … Amsacrine
Products Obiltoxaximab was approved in the United States in 2016 as an infusion product (Anthim). It has not yet been registered in many countries. Obiltoxaximab was developed with funding from national organizations and is intended primarily for the treatment of victims of a terrorist attack with anthrax spores (Strategic National Stockpile). Structure and properties Obiltoxaximab … Obiltoxaximab
Products Obinutuzumab is commercially available as a concentrate for the preparation of an infusion solution (Gazyvaro). It has been approved in many countries since 2014. Structure and properties Obinutuzumab is a recombinant, monoclonal, and humanized type II antibody against CD20 of the IgG1 isotype. It has a molecular weight of approximately 150 kDa. Obinutuzumab is … Obinutuzumab
Products Ocrelizumab was approved in many countries and in the United States in 2017 and in the EU in 2018 as an infusion concentrate (Ocrevus). Structure and properties Ocrelizumab is a humanized IgG1 monoclonal antibody with a molecular mass of 145 kDa. It is produced by biotechnological methods. Ocrelizumab is the successor agent to rituximab … Ocrelizumab
Products Catridecacog is used as a powder and solvent for the preparation of a solution for injection (NovoThirteen). It was approved in many countries in 2012. Structure and properties Catridecacog is the recombinant blood clotting factor XIII A subunit and is equivalent to the human FXIII A subunit. Effects Catridecacog (ATC B02BD11) is effective against … Catridecacog